Loading
A phase 1/2 trial of AMP945 ascending doses in pancreatic ductal adenocarcinoma, run by Amplia Therapeutics Limited, active and no longer recruiting.
ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05355298 by Amplia Therapeutics Limited, with 62 participants enrolled, started 2022-05-31 and due to reach its primary completion in 2027-02-01. Interventions recorded: AMP945 ascending doses and AMP945 RP2D.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Amplia Therapeutics, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/